OABI vs. ABSI, MXCT, INNV, ZJYL, KRRO, VALN, CALT, ALT, CSTL, and PAHC
Should you be buying OmniAb stock or one of its competitors? The main competitors of OmniAb include Absci (ABSI), MaxCyte (MXCT), InnovAge (INNV), Jin Medical International (ZJYL), Korro Bio (KRRO), Valneva (VALN), Calliditas Therapeutics AB (publ) (CALT), Altimmune (ALT), Castle Biosciences (CSTL), and Phibro Animal Health (PAHC). These companies are all part of the "medical" sector.
OmniAb (NASDAQ:OABI) and Absci (NASDAQ:ABSI) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, analyst recommendations, valuation, media sentiment, profitability, earnings, risk and community ranking.
OmniAb has a beta of -0.18, indicating that its share price is 118% less volatile than the S&P 500. Comparatively, Absci has a beta of 2.36, indicating that its share price is 136% more volatile than the S&P 500.
Absci received 4 more outperform votes than OmniAb when rated by MarketBeat users. However, 100.00% of users gave OmniAb an outperform vote while only 52.50% of users gave Absci an outperform vote.
72.1% of OmniAb shares are held by institutional investors. Comparatively, 52.1% of Absci shares are held by institutional investors. 7.0% of OmniAb shares are held by insiders. Comparatively, 11.6% of Absci shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
OmniAb has a net margin of -148.16% compared to Absci's net margin of -1,933.65%. OmniAb's return on equity of -15.41% beat Absci's return on equity.
OmniAb has higher revenue and earnings than Absci. OmniAb is trading at a lower price-to-earnings ratio than Absci, indicating that it is currently the more affordable of the two stocks.
OmniAb presently has a consensus target price of $9.00, indicating a potential upside of 103.16%. Absci has a consensus target price of $9.25, indicating a potential upside of 107.63%. Given Absci's higher probable upside, analysts plainly believe Absci is more favorable than OmniAb.
In the previous week, OmniAb and OmniAb both had 3 articles in the media. OmniAb's average media sentiment score of 0.56 beat Absci's score of 0.30 indicating that OmniAb is being referred to more favorably in the media.
Summary
OmniAb beats Absci on 9 of the 15 factors compared between the two stocks.
Get OmniAb News Delivered to You Automatically
Sign up to receive the latest news and ratings for OABI and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding OABI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
